Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novavax, Inc.

https://novavax.com/

Latest From Novavax, Inc.

Pfizer/BioNTech COVID-19 Vaccine Will Miss US Election, Bourla Clarifies

Pfizer CEO says that an EUA request for its COVID-19 vaccine is unlikely before late November. Analyst calls Pfizer’s development pace an encouraging sign it could be a more nimble company.

Coronavirus COVID-19 Drug Approval Standards

Pfizer’s First COVID-19 Vaccine Results Might Be Just Days Away - But Patience Could Pay Off

Analysts are confident that Pfizer/BioNTech’s mRNA vaccine will prove its safety and efficacy – but waiting a little longer for more robust data could be for the best.

Clinical Trials Commercial

The Race To Develop A COVID-19 Vaccine: The Finish Line Approaches

Updated: a graphic tracker of key developments from the leading vaccine candidates.

Companies Clinical Trials

Coronavirus Update: As Trump Leaves Hospital, White House Blocks FDA Vaccines Guidance

As the clock ticks down to the US election day on 3 November, President Trump maintains that the first COVID-19 vaccine emergency use approval is imminent. Meanwhile, Fujifilm Toyama's Avigan is near to Japanese approval.

Coronavirus COVID-19 Vaccines
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Liposomes
  • Other Names / Subsidiaries
    • CPL Biologicals Pvt. Ltd. (Joint Venture with Cadila)
    • Isconova AB
    • Novavax AB
UsernamePublicRestriction

Register